AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-...

Press/Media: Press / Media

PeriodNov 16 2015

Media coverage

103

Media coverage

  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-...
    Media name/outletCNN Money
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletReuters
    CountryUnited Kingdom
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletPR Newswire
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletIndividual.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletIndividual.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletNasdaq
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWall Street Select
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletTown Hall
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletRCL Advisors
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletReliance Trust
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWall Street Business Network
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletSearchBug
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWorldNetDaily
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletMarketplace
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletUlitzer
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletUlitzer
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletSys-Con Media
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational..
    Media name/outletADVFN India
    CountryIndia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletTickerTech.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletBio-Medicine
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletBarchart
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletPharmacy Choice
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletIndianapolis Business Journal
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletU-T San Diego
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletPR Newswire UK
    CountryUnited Kingdom
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletFox 19
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWSFA
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKFVE
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKCBD
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWAND TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWLOX
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletState Journal
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKOLD-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletABC6.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWAFF
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWALB 10
    CountryGeorgia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWLBT
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKRHD TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWIS-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKPLC TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKXXV-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWFLX Fox 29
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletHawaii News Now
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletNebraska TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outlet14 WFIE
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWMCTV.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWFMJ 21 - TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKXNet.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKiiiTV3.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKHQ Right Now
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWVNS
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletABC News 4 Charleston
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKTRE
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWSFX-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletFOX 14 TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKSLA
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletCW Richmond WUPV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKYTX CBS 19
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKTEN.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKFMB-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKTVN
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletGTN News
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKFVS12
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outlet35 WSEE
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWECT TV-6
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKSTC-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKait 8
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWBOY
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKLTV 7
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKCEN HD
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWDAM-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletNBC12 Online
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletFox41.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletAZ-TV7
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outlet12 News Now
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKUSI.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWLTZ 38
    CountryGeorgia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWBOC TV 16
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKSWO
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outlet19 Action News
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKOTV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKNDO KNDU
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKAUZ
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWTOL-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKWES NewsWest 9
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWave 3
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletKuam News 8
    CountryGuam
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outlet3 WRCB-TV
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWTVM
    CountryGeorgia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletMyFoxTallahassee.com
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWXTX Fox 54
    CountryGeorgia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWAFB
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWTOC TV
    CountryGeorgia
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWTRF
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletNews 9
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletLive 5 WCSC
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletWMBF
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad
  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
    Media name/outletInformazione.it
    CountryItaly
    Date11/16/15
    PersonsFred Poordad